Johnson & Johnson (JNJ) announced results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

Speakers on precursor disease addressed distinctions between MGUS and smoldering multiple myeloma, risk stratification, and ...

Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced three-year follow-up data from the Phase 3 CARTITUDE-4 study ...

Johnson & Johnson's recent studies reveal impressive response rates for Talvey in combination with Tecvayli and other ...

Multiple myeloma patients with COVID-19 have high rates of hospitalization, ICU admission, and death, according to researchers.

Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...

Patti Scialfa, Bruce Springsteen’s wife, recently shared that she was diagnosed in 2018 with a type of blood cancer known as ...

Results for the company's Cepheus phase 3 trial showed a 60.9% improvement in eliminating cancer cells and a 43% reduction in the cancer progressing or causing death when its treatmentis used in ...

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.